A Phase 2 Single-Dose Study to Evaluate Safety and Efficacy of CS-1103 in Participants With Methamphetamine Use Disorder Not Seeking Treatment Receiving a Single Dose of Methamphetamine

The purpose of the study is to evaluate the safety, efficacy, and pharmacokinetics of four single, increasing doses of CS-1103, given by intravenous (IV) infusion in otherwise healthy, non-treatment seeking participants with methamphetamine use disorder in the presence of a clinically relevant dose of methamphetamine HCl (30 mg IV).

Start Date01 Mar 2025

Sponsor / Collaborator

Clear Scientific, Inc.

[+1]

NCT05971043

/ Not yet recruitingNot ApplicableIIT

Skin Disorders in Patients Using Methamphetamine

1. To detect the skin diseases in patients using methamphetamine

Start Date03 Aug 2023

Sponsor / Collaborator

Assiut University

IRCT20120502009620N2

/ RecruitingNot ApplicableIIT

Comparing the Effect of Transcranial Direct Current Stimulation (tDCS) With Cognitive-Behavioral therapy (CBT) Interventions on the stress and anxiety and depression and relapse in abstinent methamphetamine-dependent subjects in Farabi Hospital.

Start Date23 Jul 2022

Sponsor / Collaborator

Kermanshah University of Medical Sciences

100 Clinical Results associated with Methamphetamine Hydrochloride

100 Translational Medicine associated with Methamphetamine Hydrochloride

100 Patents (Medical) associated with Methamphetamine Hydrochloride

13,566

Literatures (Medical) associated with Methamphetamine Hydrochloride

13 Apr 2025·Analytical Letters

Influence of the Capillary Design and Conditions upon the Transmission Efficiency of a Portable Ion Trap Mass Spectrometer

Author: Hong, Huanhuan ; Chen, La ; Li, Gangqiang ; Wen, Luhong ; Kuang, Lvying ; Huang, Zhixiang

The capillary is a widely used atm. pressure interface in mass spectrometers that may be heated to enhance the desolvation of ions.In this study, the ion transmission efficiency of a portable ion trap mass spectrometer was investigated using capillaries with different inner diameters and temperatures, different vacuum pressures, and different ion optics designs.Due to the incomplete desolvation and the space charge effect inside the miniature ion funnel, the increase of ion intensities with the inner diameter of the capillary leveled off when the inner diameter of the capillary was larger than 0.37 mm.With the increase of capillary temperature, the ion intensities first increase due to better desolvation and then decrease due to greater diffusion loss.The optimal temperature of the capillary increases with the inner diameter of the capillary and the mass-to-charge ratio of ion.In addition, the pressures of different vacuum stages also exerted remarkable effects on the sensitivity of the portable mass spectrometer.From the perspective of instrument miniaturization, optimal transmission efficiency can be obtained when the first-stage vacuum pressure is maintained from 4 to 6 mbar.For a capillary with an inner diameter of 0.37 mm, the background of mass spectrum can be significantly reduced by replacing the pinhole behind the ion funnel with an off-axis skimmer.

01 Mar 2025·Drug and Alcohol Review

Exploring experiences of talk therapies among gay and bisexual men seeking to reduce or abstain from using crystal methamphetamine in the context of chemsex

Article

Author: Degenhardt, Louisa ; Bourne, Adam ; Stirling, Robert ; Ezard, Nadine ; Hammoud, Mohamed ; Maher, Lisa ; Prestage, Garrett ; Siefried, Krista J. ; Xiao, Bo Justin ; Varma, Rick ; Freestone, Jack

AbstractIntroductionSome gay and bisexual men who have sex with men (GBMSM) who use drugs to enhance sex (chemsex/party and play) may experience harms and seek talk therapies. GBMSM who practice chemsex may not access drug services because of anticipated stigma and the perception that these services lack chemsex expertise. Barriers to services are documented, however, little is known about the service experiences of chemsex engaged GBMSM.MethodsSemi‐structured interviews were conducted with 24 participants reporting current practice of sexualised use of methamphetamine and/or gamma hydroxybutyrate. Interviews explored experiences of counselling and psychology services, participant's treatment goals and challenges. Data were transcribed verbatim and analysed in NVIVO14 with a qualitative description methodology.ResultsMost in our study sought to reduce the frequency of methamphetamine use and used methamphetamine only in sexual contexts. When engaging with counsellors and psychologists in alcohol and other drug or mental health services for the general adult population, most censored the sexual drivers and types of sexual behaviours incumbent in their methamphetamine use. Participants' reliance on drugs for sex was spoken about as a major barrier to reducing methamphetamine. Sexual self‐censorship within services inhibited participants' abilities to access meaningful support and achieve treatment goals.Discussion and ConclusionsCounsellor and psychologists working with GBMSM around drug use, must ask about context of drug use and sex. Training and supervision around sexual therapies for those working alongside GBMSM who practice chemsex may be beneficial. Research on treatment approaches to support the sexual wellbeing of people who practice chemsex is required.

01 Mar 2025·Pharmacology Biochemistry and Behavior

NMDA-induced lesions of the nucleus accumbens core increase the innately rewarding saccharin solution intake and methamphetamine-induced conditioned place preference but not conditioned taste aversion in rats

Article

Author: Wu, Chi-Wen ; Huang, Andrew Chih Wei ; Wang, Ying-Chou ; Li, Wei-Lun ; Cheng, Cai-N ; Kozłowska, Anna

The role of the nucleus accumbens (NAc) core in determining the valence of innately rewarding saccharin solution intake, methamphetamine (MAMPH)-induced conditioned taste aversion (CTA), and conditioned place preference (CPP) reward remains unclear. The present study utilized the "pre- and post-association" experimental paradigm (2010) to test whether the rewarding and aversive properties of MAMPH can be modulated by an N-methyl-D-aspartic acid (NMDA) lesion in the NAc core. Moreover, it tested how an NAc core NMDA lesion affected the innate reward of saccharin solution intake. The results demonstrate that MAMPH could simultaneously induce an aversive CTA and a rewarding CPP effect, supporting the paradoxical effect hypothesis of abused drugs, in particular amphetamine. Meanwhile, the NMDA-lesioned NAc core increased the reward effect of CPP but did not alter the aversive CTA effect. The NAc core NMDA lesion also enhanced the innate reward of saccharin solution intake. The NAc core therefore seemingly plays an inhibitory role in the innate reward of saccharin solution intake and in the CPP effect. The paradoxical effect hypothesis of abused drugs provides some explanations for the present data in the case of MAMPH administrations. The NAc core may play an essential role in modulating the rewarding but not the aversive properties of MAMPH. The present findings could contribute to the understanding and eventual advancement of clinical interventions for drug addiction and the development of novel pharmacological treatments.

News (Medical) associated with Methamphetamine Hydrochloride

01 Feb 2025

·www.globenewswire.com

Intelligent Bio Solutions Partners with IVY Diagnostics to Expand in Europe’s $3.6 Billion Drug Screening Market and in Middle Eastern Regions

Jan. 28, 2025 -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced the strengthening of its foothold throughout Europe and the Middle East through its partnership with IVY Diagnostics Srl (“IVY Diagnostics”). As a key distributor, IVY Diagnostics is playing an integral role in expanding the adoption of INBS' Intelligent Fingerprinting Drug Testing Solution across Europe and the Middle East, with a particular focus on drug rehabilitation and law enforcement applications. According to Grand View Research, the European and Middle Eastern drug screening markets are projected to grow significantly by 2030, with Europe expected to reach $3.6 billion1 and the Middle East and Africa $432.7 million2. This growing demand emphasises the strategic importance of INBS' partnership with IVY Diagnostics. IVY Diagnostics, a well-known consulting and distribution company within the diagnostics, life sciences and pharmaceutical sectors, has collaborated with another Italian distributor to secure a tender to provide INBS' drug screening technology for drug rehabilitation programs across Italy. The solution offers a non-invasive, rapid, and hygienic method for drug screening, which has been well received by rehabilitation centres aiming to enhance their testing protocols. In addition to its success in rehabilitation services, INBS' drug screening system is currently undergoing a trial with the local police force in Turin. The trial aims to explore the effectiveness of fingerprint-based drug testing in roadside screening initiatives, offering a more efficient, less invasive alternative to the traditional methods currently used. As the demand for drug screening solutions rises across Europe and the Middle East, INBS’ collaboration with IVY Diagnostics positions the Company to effectively capture new opportunities. IVY Diagnostics serves as INBS' primary contact in Europe, leveraging its extensive network of distributors and expertise in identifying and vetting new partners across key regions, including Romania, Hungary, Slovakia, Austria, and Scandinavia. The collaboration extends to the Middle East, targeting markets such as the UAE, Saudi Arabia, and Qatar. "Our strategic partnership with IVY Diagnostics plays a key role in introducing our fingerprint sweat-based drug screening technology to new markets and industries," said Doug Heath, Vice President of Global Sales at Intelligent Bio Solutions. "Their deep understanding of the regulatory landscape, coupled with their extensive connections across Europe and the Middle East, positions them as an invaluable partner in our mission to provide safer and more efficient drug testing solutions worldwide." IVY Diagnostics is enthusiastic about raising awareness around the benefits of fingerprint-based drug testing technology, working closely with stakeholders to highlight its applications in sectors requiring stringent drug testing protocols. The efforts of IVY Diagnostics align with INBS' vision to transform drug screening through innovative, non-invasive, and accessible solutions. IVY Diagnostics Srl is a dynamic company operating in the diagnostics and life sciences sectors, with a focus on Point of Care Testing (POCT) and rapid testing solutions. Since its foundation in 2013, IVY Diagnostics has grown steadily, expanding its portfolio to include proprietary and distributed diagnostic products, as well as consulting services aimed at supporting clients worldwide. The company is recognized for its commitment to innovation and quality, having launched advanced solutions such as the easyTOX™ drug detection system and established a strong presence in international markets. IVY Diagnostics combines flexibility and customer focus to deliver impactful solutions for healthcare professionals and organizations globally. Intelligent Bio Solutions Inc. (NASDAQ: INBS) is a medical technology company delivering innovative, rapid, non-invasive testing solutions. The Company believes that its Intelligent Fingerprinting Drug Screening System will revolutionize portable testing through fingerprint sweat analysis, which has the potential for broader applications in additional fields. Designed as a hygienic and cost-effective system, the test screens for the recent use of drugs commonly found in the workplace, including opiates, cocaine, methamphetamine, and cannabis. With sample collection in seconds and results in under ten minutes, this technology would be a valuable tool for employers in safety-critical industries. The Company’s current customer segments outside the US include construction, manufacturing and engineering, transport and logistics firms, drug treatment organizations, and coroners. ____________________ Hyperlinks and website references in this release are provided for convenience only and do not incorporate the referenced content into this release. 1 Grand View Research. Europe Drug Screening Market Size & Outlook, 2023-2030. Available at: https://www.grandviewresearch.com/horizon/outlook/drug-screening-market/europe 2 Grand View Research. Middle East and Africa Drug Screening Market Size & Outlook. Available at: https://www.grandviewresearch.com/horizon/outlook/drug-screening-market/mea The content above comes from the network. if any infringement, please contact us to modify.

Diagnostic Reagents

08 Nov 2024

·www.fiercepharma.com

FDA proposes ban on main ingredient in many OTC decongestants

The FDA has proposed a ban on over-the-counter oral decongestant medicines containing the ingredient phenylephrine, potentially affecting some common brands such as Sudafed, NyQuil, Mucinex and Benadryl. Common oral medicines that have been used for decades as decongestants such as Sudafed, NyQuil and Benadryl may soon be cleared from shelves as the FDA has proposed to discontinue the sale of products containing the active ingredient phenylephrine.Following up on a unanimous advisory committee vote last year, the FDA has asked for feedback on its proposal to outlaw the use of phenylephrine as an oral med.In a 16-0 vote, the Nonprescription Drugs Advisory Committee (NDAC) said in September 2023 that phenylephrine is ineffective when taken as a liquid or in a pill. The ingredient does work however when it is delivered as a nasal spray, the panel agreed. There is no concern with the safety of phenylephrine, the FDA said.“Based on our review of available data, and consistent with the advice of the advisory committee, we are taking this next step in the process to propose removing oral phenylephrine because it is not effective as a nasal decongestant,” Patrizia Cavazzoni, M.D., the director of the FDA’s Center for Drug Evaluation and Research (CDER), said in a release.The advisory committee recommendation was based on data that showed that phenylephrine performed no better than placebo in relieving congestion when taken orally. The compound is designed to reduce the swelling of blood vessels, but the NDAC concluded that when it is received by way of the mouth, not enough of the drug reaches the nasal passages.If the agency makes a final determination—after reviewing public comments—that phenylephrine is not effective, it will issue a final order banning its inclusion in oral medicines. The agency said it would provide manufacturers a grace period to either reformulate their drugs or remove them from the market.The Consumer Healthcare Products Association CEO Scott Melville said in a statement that the organization was “disappointed” by the FDA’s proposal and pointed out that it was “at odds with previous FDA decisions and Advisory Committee recommendations.” For decades, people have relied on oral PE to relieve their nasal congestion,” Melville said. “We believe Americans deserve access to safe and effective OTC medicines and the option to choose the products they prefer for self-care.”Products that include the ingredient—roughly 250 of them—generated approximately $1.8 billion in sales in 2022. Some products contain phenylephrine as a single active ingredient. Others include phenylephrine in combination with other agents.Last year, a month after the NDAC made its recommendations, pharmacy giant CVS said that it would no longer sell meds that contain phenylephrine as its only active ingredient. One such product is Kenvue’s Sudafed PE. “Consumers should know that a range of safe and effective drugs and other treatments is available to temporarily relieve congestion symptoms due to allergies or a common cold,” Theresa Michele, M.D., director of the Office of Nonprescription Drug Products in CDER, said. Phenylephrine is one of two oral decongestants available without prescription. Sales of the other, pseudoephedrine, were restricted in 2006 because it can be misused to make methamphetamine. Products with pseudoephedrine are still available OTC but are often behind store counters or locked away, out of the reach of consumers. There also are limitations on how many pills can be purchased during a store visit.The restrictions led to a boom in products containing phenylephrine. But soon after their rise in popularity, the FDA’s scrutiny of phenylephrine began. In 2007, the NDAC came to a similar conclusion on its ineffectiveness. While four subsequent studies showed the ineffectiveness of phenylephrine when taken as a pill, there was enough variability in the results to raise questions about how the studies were conducted.

NDA

31 Mar 2023

·www.drugs.com

ADHD Med Prescriptions Spiked Early in Pandemic

FRIDAY, March 31, 2023 -- Prescriptions for attention deficit hyperactivity disorder (ADHD) medications spiked during the COVID-19 pandemic, a new government report shows. The trend may reflect both greater awareness among adults of ADHD symptoms and increased stress driving people to get the care they need. “This report shows there is this growing population of adults who have been diagnosed with ADHD, and there is need for support for this population,” lead study author Melissa Danielson , a statistician with the U.S. Centers for Disease Control and Prevention, told NBC News . Prescriptions for ADHD have been increasing since 2016, according to the CDC researchers, who used insurance data on prescription medication for that year through 2021 in people ages 5 to 64. The study, published March 31 in the CDC publication Morbidity and Mortality Weekly Report, noted that prescriptions filled for stimulant medication increased to 4.1% in 2021 from 3.6% in 2016 among those enrolled in employer-sponsored insurance. The increase was even more pronounced in certain age groups: Among adolescent and adult females ages 15 to 44 and males ages 25 to 44, prescriptions grew 10% from 2020 to 2021. They also rose nearly 20% among females in an even narrower age range, 20 to 24. The medications tracked in the analysis were stimulants sold under the brands Dexedrine and Adderall, methamphetamine under the brand Desoxyn , and methylphenidate , known as Ritalin . A few factors may play into the increases, including greater awareness about symptoms, particularly symptom differences in women; an increase in all mental health diagnoses during the pandemic, and increased access because of changes in how ADHD is diagnosed, NBC News reported. Telehealth may also have played a role. “People tend to seek out diagnoses during times of stress and crisis, and we have anecdotal evidence that there was a significant increase in people seeking diagnoses during the pandemic,” Joshua Langberg , an ADHD specialist and director of the Center for Youth Social Emotional Wellness at Rutgers University in New Jersey, told NBC News. The changes in how ADHD is diagnosed were due to a 2013 update in guidelines in the Diagnostic and Statistical Manual of Mental Disorders. Among the changes included are ADHD symptoms starting later, at age 12 rather than at age 7, to be eligible for a diagnosis, NBC News reported. Adults also need to have fewer symptoms to qualify. Generally, symptoms of ADHD are inattention, hyperactivity-impulsivity, not following through on instructions, not paying close attention to details, losing things and talking excessively. Mental health providers also saw patients via telehealth during the pandemic and prescribed stimulants without seeing patients in person, NBC News reported. “That increased access allowed some people who had flown under the radar, or who said they were doing well enough, to get help,” J. Russell Ramsay , director of the Adult ADHD Treatment and Research Program at the University of Pennsylvania’s Perelman School of Medicine, told NBC News . Ramsay said there has been both over- and underdiagnosis of the disorder. “A comprehensive evaluation for ADHD is time-consuming, can be costly and it involves not just assessing for ADHD, but other things that can lead to concentration issues such as anxiety, depression and lack of sleep,” he explained. Providers sometimes have limited resources to take this into account, and some telehealth companies and pharmacies are being investigated for potentially overprescribing ADHD medication, NBC News reported. “Because ADHD occurs with other mental health disorders half the time, you have to make sure one of those is not causing symptoms of ADHD,” Dr. Lenard Adler , director of the Adult ADHD Program at NYU Langone, told NBC News . “You have to take a careful history.” Sources Morbidity and Mortality Weekly Report , March 31, 2023 NBC News Posted March 2023 Further Support and Information on COVID-19 COVID-19: Prevention & Investigational Treatments COVID-19 Support Group Coronavirus Disease Guide

100 Deals associated with Methamphetamine Hydrochloride

External Link

KEGG	Wiki	ATC	Drug Bank
-	Methamphetamine Hydrochloride	N06BA03	-

R&D Status

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Attention Deficit Disorder With Hyperactivity	United States	AJENAT PHARMACEUTICALS LLC	31 Dec 1943
Depressive Disorder	Japan	Sumitomo Pharmaceuticals Co., Ltd.	01 Jan 1941
Narcolepsy	Japan	Sumitomo Pharmaceuticals Co., Ltd.	01 Jan 1941
Schizophrenia	Japan	Sumitomo Pharmaceuticals Co., Ltd.	01 Jan 1941

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


SFN2021	Not Applicable	-	-	Methamphetamine	hnwhszjvdy(pwlsggmlwb) = 0.1 mg/kg LEV increased the time spent in the drug-paired chamber, but this data did not reach statistical significance ilnebxsrmj (lliszcojrw )	-	11 Nov 2021
				Levamisole
SFN2018	Not Applicable	Methamphetamine dependence	-	Methamphetamine 0.3 mg/kg	wxzbqiyygn(ogmzkrhsvq) = lfeawkkcku rzjjqrdbhc (xsqbychoyl )	-	03 Nov 2018
				Methamphetamine 2.0 mg/kg	wxzbqiyygn(ogmzkrhsvq) = ymthebsqcp rzjjqrdbhc (xsqbychoyl )
SFN2017	Not Applicable	Toxicity	-	Alcohol	ajxboadzoq(ytydefbzxx) = xhcdtyjghm ayfsmzloem (nkrcciphnj ) View more	-	11 Nov 2017
				Methamphetamine	iveyvoqyrk(oswxzmcbpv) = zdrihuuxbv nkerhxfaxw (cfvrsaypad ) View more
SFN2015	Not Applicable	Methamphetamine dependence	-	Methamphetamine 1.0 mg/kg	yebmdxthtv(udpvtnslxv) = ltrpllemfc bbfidsgpec (mllxnhyfsz )	-	19 Oct 2015
				Methamphetamine 2.0 mg/kg	azneljjkqx(cpmqpflupt) = sgfmxmafmp vjjmurlptk (fzvmdbyoqk )
ISC2013	Not Applicable	Cerebral Hemorrhage methamphetamine abuse	384	Methamphetamine (Native Hawaiians and other Pacific Islanders)	xrkfkdlsbi(qitktbdfdz) = dkdyjqvmyg bjdpacdgfg (rtxvxhfshz ) View more	-	01 Feb 2013
				Methamphetamine (Non-Hispanic whites)	xrkfkdlsbi(qitktbdfdz) = bgvuhgcbdq bjdpacdgfg (rtxvxhfshz ) View more
SFN2010	Not Applicable	Memory Disorders	-	Saline	(nhdwwuzfae) = karlihgmkr dcrjoxaltq (ayenvszalo )	-	14 Nov 2010
				Methamphetamine	(nhdwwuzfae) = wmdwogzwwp dcrjoxaltq (ayenvszalo )
SFN2008	Not Applicable	Methamphetamine dependence	-	Methamphetamine	rvnvtzplza(wzsvndwilv) = The tonic current was significantly increased after chronic meth treatment and withdrawal bouotrluxo (ighlfyzlii )	-	17 Nov 2008
SFN2005	Not Applicable	Methamphetamine dependence	-	Methamphetamine	yhikjlyhvi(scnvpiygup) = uwxdouaxyy vpqwnmvien (hazjyvlsob ) View more	-	15 Nov 2005
				Placebo	yhikjlyhvi(scnvpiygup) = hctthjtazz vpqwnmvien (hazjyvlsob ) View more
SFN2003	Not Applicable	-	-	Methamphetamine	hnrpwfkfdr(jktmcszxgp) = wvitosibul dmmxdxmfwc (bzjzvgknuu )	-	12 Nov 2003
				L-NAME (NOs inhibitor)	eebkztkcdu(fzxyohwmax) = icmoyayxvv kiwtojmlxd (fodfrgeqsd )
SFN2003	Not Applicable	-	-	Methamphetamine	ntppdbdqcs(mamlvgzgej) = tlzczyaakg uwhtvtgyfh (uckjakjqda )	-	09 Nov 2003
				Amphetamine	ntppdbdqcs(mamlvgzgej) = wgrfygjiqw uwhtvtgyfh (uckjakjqda )

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis